JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Kodu・Aktsiate loetelu・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Suletud

1.88 1.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.86

Max

1.88

Põhinäitajad
By Trading Economics
P/E Sektori keskmine	2.457 40.048
Aktsiakasum	-0.5
Töötajad	8

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2025

Turustatistika
By TradingEconomics
Turukapital	3.7M 12M
Eelmine avamishind	0.8
Eelmine sulgemishind	1.88

Minerva Neurosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. aug 2025, 17:41 UTC

Tulu

Suurimad hinnamuutused turgudel

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

1. aug 2025, 17:40 UTC

Tulu

Suurimad hinnamuutused turgudel

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

2. aug 2025, 15:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- Update

2. aug 2025, 13:29 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 13:10 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 12:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 12:53 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2. aug 2025, 12:52 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2. aug 2025, 12:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. aug 2025, 22:31 UTC

Tulu

MicroStrategy Stock Drops 9%. New Equity Guidelines Could Be the Reason. -- Barrons.com

1. aug 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. aug 2025, 20:28 UTC

Omandamised, ülevõtmised, äriostud

EOG Resources Completes $5.6B Purchase of Encino Acquisition Partners

1. aug 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

1. aug 2025, 20:08 UTC

Market Talk

U.S. Stocks Tumble as U.S. Jobs Market Weakens, New Tariffs Hit -- Market Talk

1. aug 2025, 19:54 UTC

Market Talk

Mexico Manufacturing Indexes Mixed in July -- Market Talk

1. aug 2025, 19:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. aug 2025, 19:42 UTC

Market Talk

Treasury Yields Start Month With Jobs-Driven Decline -- Market Talk

1. aug 2025, 19:40 UTC

Market Talk

Global Energy Roundup: Market Talk

1. aug 2025, 19:40 UTC

Market Talk

U.S. Natural Gas Futures Hold Above Key Support -- Market Talk

1. aug 2025, 19:19 UTC

Market Talk

Livestock Brings Positive Momentum Into August -- Market Talk

1. aug 2025, 19:13 UTC

Market Talk

Crude Falls on Soft U.S. Jobs Data, OPEC+ Output Expectations -- Market Talk

1. aug 2025, 19:07 UTC

Omandamised, ülevõtmised, äriostud

Danone to Explore Buying Lifeway Foods. The Third Time Could Be Different. -- Barrons.com

1. aug 2025, 18:38 UTC

Market Talk

Grains Shrug Off Lower Dollar -- Market Talk

1. aug 2025, 18:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. aug 2025, 17:53 UTC

Omandamised, ülevõtmised, äriostud

Correction to M&A Is Back. These Stocks Could Be Targets. -- Barrons.com

1. aug 2025, 17:52 UTC

Market Talk

Gold Finishes Higher Amid Weak July Hiring and Tariffs -- Market Talk

1. aug 2025, 17:38 UTC

Market Talk

U.S. Oil Rig Count Down By 5 to 410 -- Market Talk

1. aug 2025, 17:06 UTC

Tulu

Earnings Season Is Going Really Well. Don't Overthink It. -- Barrons.com

1. aug 2025, 16:55 UTC

Tulu

Big Takeaways From Big Tech Earnings -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Minerva Neurosciences Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Minerva Neurosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Ettevõttest Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.